Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The FDA has approved a live attenuated oral vaccine to prevent cholera (serogroup O1) in adults aged 18 to 64 visiting cholera-affected areas.
Vaxchora is the only FDA-approved vaccine for cholera prevention. It is given as a single liquid dose (roughly 3 oz) at least 10 days before travel.
Vaxchora's efficacy was demonstrated in a randomized trial in which roughly 130 U.S. adults were given either the vaccine or placebo and then challenged with oral Vibrio cholerae. The vaccine was 90% effective in those challenged 10 days after vaccination and 80% effective in those challenged 90 days after vaccination. Vaxchora's safety was demonstrated in four placebo-controlled trials comprising over 3200 participants. The most common adverse reactions included tiredness, headache, abdominal pain, nausea and vomiting, appetite loss, and diarrhea.
Of note, Vaxchora's safety and effectiveness have not been established in immunocompromised patients.
Comment
LINK(S):
FDA news release (Free)
Vaxchora prescribing information (Free PDF)
Background: NEJM Journal Watch Infectious Diseases coverage of a single-dose, inactivated cholera vaccine in Bangladesh (Free)